Analysis of the PSM cohort comprising T2DM + HTN and CAD + T2DM + HTN patients categorized by short-term SGLT2 inhibitor use showed SGLT2 inhibitor recipients had 0.732-fold lower MRV(Venular)C than non-recipients (P < 0.001, 95% CI: 0.653–0.821), with reduced MRV(Venular)C at 0.5–1.0PD (OR = 0.959, P = 0.006), 1.0–1.5PD (OR = 0.926, P < 0.001), 1.5–2.0PD (OR = 0.921, P < 0.001), and 2.0–2.5PD (OR = 0.956, P = 0.005) (95% CIs: 0.930–0.988, 0.890–0.964, 0.881–0.963, 0.926–0.987 respectively). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.